Pharmacokinetics and pharmacodynamics of glimepiride in type 2 diabetic patients: Compared effects of once- versus twice-daily dosing

Endocrine Journal

Volumn 54, Issue 4, 2007, Pages 571-576

  Matsuki, Michihiro ^a   Matsuda, Masafumi ^a   Kohara, Kenji ^a   Shimoda, Masashi ^a   Kanda, Yukiko ^a   Tawaramoto, Kazuhito ^a   Shigetoh, Makoto ^a   Kawasaki, Fumiko ^a   Kotani, Kou ^a   Kaku, Kohei ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Glimepiride; Pharmacodynamics; Pharmacokinetics; Type 2 diabetes

Indexed keywords

C PEPTIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TIME;

AGED; BLOOD GLUCOSE; C-PEPTIDE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; SULFONYLUREA COMPOUNDS;

EID: 34548688661     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K06-052     Document Type: Article

References (20)

1. Geisen K (1988) Special pharmacology of the new sulfonylurea glimepiride. Arzneimittelorschung Drug Res 38: 1120-1130.
2. Drager E (1995) Clinical profile of glimepiride. Diabetes Res Clin Prac 28 (Suppl): S139-S146.
3. Muller G, Stoh Y, Geisen K (1995) Extrapancreatic effects of sulfonylureas - a comparison between glimepiride and conventional sulfonylureas. Diabetes Res Clin Prac 28 (Suppl): S114-S137.
4. Rosenstock J, Samols E, Muchmore DB, Schneider J (1996) Glimepiride, a new once-daily sulfonylurea. Diabetes Care 19: 1194-1199.
5. Badian M, Korn A, Lehr KH, Malerczyk V, Waldhausl W (1994) Absolute bioavailability of glimepiride (Amaryl) after oral administration. Drug Metab Drug Interact 11: 331-339.
6. Malerczyl V, Badian M, Korn A, Lehr KH, Waldhausl W (1994) Dose linearity assessment of glimepiride (Amaryl) tablets in healthy volunteers. Drug Metab Drug Interact 11: 341-357.
7. Rosenkranz B, Profozic V, Metelko Z, Mrzljak V, Malerczyk V (1996) Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia 39: 1617-1624.
8. Sonnenberg GE, Garg DC, Weidler DJ, Dixon RM, Jaber LA, Bowen AJ, DeChemey GS, Mullican WS, Stonesifer LD (1997) Short-term comparison of once-versus twice-daily administration of glimepiride in patients with non-dependent diabetes mellitus. Ann Pharmacother 31: 671-676.
9. Ferner R, Chaplin S (1987) The relationship between the pharmacokinetics effects of oral hypoglycemic drugs. Clin Pharmacokin 12: 379-401.
10. Marchetti P, Navalesi R (1989) Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. Clin Pharmacokin 16: 100-128.
11. Malerczyk V, Badian M, Korn A, Lehr KH, Waldhausl W (1994) Dose linearity assessment of glimepiride tablets in healthy volunteers. Drug Metab Drug Interact 11: 341-357.
12. 3H] glimepiride. Biochim Biophys Acta 1191: 278-290.
13. Kosaka K, Kikuchi M, Kuzuya T, Akanuma Y, Takiguchi K, Ishihara T, Ohashi Y (1997) Effect of novel hypoglycemic agent, AY4166, on post-prandial blood glucose and pharmacokinetics of NIDDM patients. Clin Pharmacol Ther 7: 653-668 (In Japanese).
14. Hanefeld M, Dickinson S, Bouter KP, Guitard C (2000) Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care 23: 202-207.
15. Hollander PA, Schwartz SL, Gatlin MR, Haas SJ, Zheng H, Foley JE, Dunning BE (2001) Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 24: 983-988.
16. Kurtz SMS (1990) Adherence to diabetes regimens: empirical status and clinical applications. Diabetes Educ 16: 50-56.
17. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL (1989) How often is medication taken as prescribed? A novel assessment technique. JAMA 261: 3273-3277.
18. Pullar T, Birtwell AJ, Wiles PG, Hay A, Feely MP (1988) Use of pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice, or three times daily. Clin Pharmacol Ther 44: 540-545.
19. Draeger KE, Wernicke-Panten K, Lomp HJ, Schuler E, Rosskamp R (1996) Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide. Horm Metab Res 28: 419-425.
20. Paes AH, Bakker A, Soe-Agnie CJ (1997) Impact of dosage frequency on patient compliance. Diabetes Care 20: 1512-1517.